Welcome to our dedicated page for Gain Therapeutics SEC filings (Ticker: GANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gain Therapeutics, Inc. (GANX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company and an emerging growth company, Gain Therapeutics uses SEC reports to provide detailed information on its business, financial condition and progress in developing allosteric small molecule therapies such as GT-02287 for Parkinson’s disease.
Through this page, readers can access annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s operations, risk factors, research and development activities, and financial statements. Current reports on Form 8-K capture material events, including clinical data updates from the Phase 1b study of GT-02287, financial results, changes in corporate governance, amendments to the certificate of incorporation, and other significant corporate actions.
Investors interested in capital structure and corporate actions can review filings that discuss increases in authorized shares of common stock, shareholder meeting results, and other matters submitted to a vote of security holders. These documents help explain how Gain Therapeutics manages its equity base as it advances its clinical and preclinical programs.
For those tracking clinical development disclosures, 8-K filings and related exhibits often summarize preliminary safety and tolerability findings, exploratory biomarker endpoints such as glucosylsphingosine (GluSph) changes in cerebrospinal fluid, and recommendations from independent data monitoring committees. These filings complement the company’s press releases by providing formal regulatory context for key milestones in the GT-02287 program.
Stock Titan enhances access to these documents with AI-powered summaries that highlight important points from lengthy filings, helping readers interpret complex sections without replacing the original text. Real-time updates from the EDGAR system ensure that new 10-K, 10-Q, 8-K and other forms are available as they are filed, while tools for viewing insider-related filings such as Form 4, when present, can assist in monitoring transactions by directors and officers of Gain Therapeutics.
Gain Therapeutics (GANX) furnished a virtual KOL event presentation under Item 7.01 Regulation FD. On October 14, 2025, the company hosted “Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287,” featuring Karl Kieburtz, M.D., M.P.H. (University of Rochester) and Kenneth Marek, M.D. (Institute for Neurodegenerative Disorders).
The slide deck from the event was furnished as Exhibit 99.1. The information provided under Item 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed filed or subject to Section 18 liability, nor incorporated by reference unless specifically referenced.
Gain Therapeutics, Inc. reported a change in its Board of Directors. On October 6, 2025, director Eric Richman resigned from the Board effective immediately. The company states that his resignation was not due to any disagreement with Gain Therapeutics regarding its operations, policies, or practices. On October 7, 2025, in connection with his departure, the company reduced the size of the Board from eight to seven members, reflecting the vacancy without appointing a replacement.
Gain Therapeutics reported preliminary results from its ongoing Phase 1b study of GT-02287 in people with Parkinson’s disease, with or without a GBA1 mutation. After 90 days of dosing, GT-02287 has been safe and generally well tolerated, with no treatment-emergent serious adverse events. Some participants showed transient increases in alkaline phosphatase and other liver enzymes, which returned to normal even while treatment continued.
The 21 participants include treatment-naïve patients, individuals on deep brain stimulation, and most on levodopa and other Parkinson’s drugs. Several participants experienced improvements in their MDS-UPDRS Part II and III scores by Day 90, while mean Part I scores were unchanged. The company notes that the mean improvement in Parts II and III by Day 90, not seen by Day 30, suggests a potential disease-slowing effect consistent with preclinical models and the proposed mechanism of GT-02287. Plasma pharmacokinetics were consistent across sampled participants and within the projected therapeutic range.
A data monitoring committee has twice recommended continuing the study, and Australian health authorities have approved an extension allowing patients to be treated for up to 12 months.
Gain Therapeutics reported operating losses and tightened liquidity in the first half of 2025 while continuing clinical development of its lead program. For the six months ended June 30, 2025 the company recorded a $10.34 million net loss, with total operating expenses of $9.46 million. Cash and cash equivalents were $6.69 million at June 30, 2025, down from $10.39 million at year-end 2024, and total assets were $9.83 million versus total liabilities of $6.14 million, leaving stockholders' equity of $3.70 million.
The company disclosed a going concern assessment, stating its June 30, 2025 cash is insufficient to fund operations for 12 months and that it will need additional capital to continue beyond Q1 2026. Management noted recent financings including ATM sales and a July 2025 public offering that generated net proceeds (July offering net proceeds of $6.1 million plus an additional $1.0 million from over-allotment) and described actions to optimize costs and pursue collaborations. The lead clinical candidate GT-02287 completed a Phase 1 study (n=72) that was reported as safe and generally well tolerated, supporting further development.
Gain Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Current Report. The filing also references an Interactive Data File as Exhibit 104.
The registrant indicates it is an emerging growth company and its common stock trades under GANX on The NASDAQ Stock Market. The company states the press release and related information are furnished and therefore are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except by specific reference. This 8-K does not include the financial statements or numeric results within its text.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing the award of a stock option to director Khalid Islam on 06/24/2025. The option covers 15,000 shares of common stock at an exercise price of $1.79 per share and expires on 06/24/2035. According to the filing, the grant will vest in 12 equal monthly installments beginning 07/24/2025, contingent upon Mr. Islam’s continued service with the company. Following the grant, Mr. Islam beneficially owns 15,000 derivative securities directly. No non-derivative share transactions were reported.
The filing is routine and reflects a standard equity-based compensation mechanism used to align director incentives with shareholder interests. No changes to ownership structure, sales of shares, or additional material financial data were included.
Key take-away: On 06/24/2025 Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Claude Nicaise received a stock option covering 15,000 shares of common stock at an exercise price of $1.79 per share, expiring on 06/24/2035.
The option was awarded, not exercised, and therefore does not immediately affect the public float. Vesting occurs in 12 equal monthly tranches starting 07/24/2025, contingent on Mr. Nicaise’s continued service. After the grant, the director directly holds 15,000 derivative securities; no non-derivative holdings or sales were reported.
This represents routine equity compensation aimed at further aligning board incentives with shareholder interests. No cash changed hands and no other material transactions were disclosed in this filing.
Key take-away: Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Jeffrey Scott Riley received a grant of 15,000 stock options on 06/24/2025.
The option has an exercise price of $1.79 per share and expires on 06/24/2035. The transaction is coded “A” (acquisition) and represents the only derivative security currently reported for the director; no common shares were bought or sold.
Vesting schedule: the award vests in 12 equal monthly installments beginning 07/24/2025, provided Mr. Riley continues his service. Following the grant he beneficially owns 15,000 options, classified as direct ownership. No indirect holdings or Rule 10b5-1 trading plan were indicated.
Investor relevance: This filing reflects standard director compensation and does not involve open-market buying or selling. While the grant modestly increases potential future dilution, its size is immaterial relative to GANX’s total shares outstanding. The filing may signal management’s effort to align director incentives with shareholder value but is unlikely to move the stock on its own.